Congress on Hematologic Malignancies

Although treatments and cure rates have increased significantly over the past 60 years for patients with HL, it is crucial that practitioners stay up-to-date on research that can affect outcomes for their patients with this uncommon form of cancer.

The treatment options for patients with relapsed/refractory multiple myeloma are expanding rapidly, notably through clinical trial evidence supporting a number of three-drug combination regimens.

Cytogenetic and molecular data are becoming increasingly important in the individualization of treatment of patients with acute myeloid leukemia (AML).

Although advances are being made in novel therapies for patients with chronic lymphocytic leukemia (CLL), standard chemotherapy remains part of the treatment paradigm, but its role is undergoing a major shift.

Follicular lymphoma (FL) is a slow-growing and typically asymptomatic disease, characterized by many relapses.

Experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.